Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Rev Anticancer Ther. 2003 Aug;3(4):525-36.

Lipoxygenase inhibitors for the treatment of pancreatic cancer.

Author information

  • 1Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.

Abstract

Pancreatic cancer has a dismal prognosis with no effective medical therapy. Therefore, there is a need to search for novel targets for cancer prevention and treatment. The lipoxygenases oxygenate arachidonic acid and other 20-carbon fatty acids and their downstream metabolites have been found to mediate several aspects of pancreatic cancer development and growth. Therapeutic agents have been developed against various targets in the lipoxygenase pathways. Many of these were first developed for their anti-inflammatory properties and were subsequently found to have anticancer effects. Such agents include lipoxygenase and 5-lipoxygenase-activating protein inhibitors, leukotriene receptor antagonists and natural products with inhibitory effects on these pathways. Dual lipoxygenase and cyclooxygenase inhibition represents an exciting area of research and drug development.

PMID:
12934664
DOI:
10.1586/14737140.3.4.525
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center